Shots:
- J&J has entered into a definitive agreement to acquire Firefly Bio, incl. its Firelink degrader antibody conjugate (DAC) platform, expanding its oncology pipeline
- As per the deal, J&J will acquire Firefly Bio for $1B in cash, with closing expected later this year
- The Firelink DAC platform is a targeted protein degradation tech that selectively delivers potent protein degraders to KRAS-driven tumor cells while avoiding healthy tissue, with the goal of improving treatment precision & minimizing off-target toxicity
Ref: Businesswire | Image: Firefly Bio | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
